Stimulation of these receptors by GLP-1RAs may lead to cellular overgrowth, hyperplasia, chronic low-grade, or acute inflammation
by Dennis Crouch Since late 2022, the extraordinary demand for glucagon-like peptide-1 receptor agonists (GLP-1s) like Eli Lilly's tirzepatide (marketed as Mounjaro for diabetes and Zepbound for weight loss) has created a persistent nationwide shortage
37.3%), followed by diabetes mellitus (N = 27
Also, take note of how your clothes fit, your daily energy levels, and any new side effects, such as nausea or digestive discomfort
Semaglutide (Wegovy): Designed for weight loss, clinical trials show an average reduction of 1520% of body weight over 612 months with proper diet and exercise
2022, doi:10.1111/dom.14775 Zhang, Qian et al